+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are studying the effectiveness and safety of combining RC108 with Furmonertinib compared to Furmonertinib alone for treating patients with a specific type of advanced or recurrent non-small cell lung cancer NSCLC that has both EGFR mutations and MET positivity. This phase II clinical trial aims to better understand how these treatments work together for this condition. The trial involves two groups one receiving RC108 combined with Furmonertinib, and the other receiving Furmonertinib alone. Participants have unresectable locally advanced or recurrent metastatic NSCLC with certain EGFR mutations and MET positivity. Treatment and monitoring occur over several months, with careful evaluation of drug effects and safety. Participants will undergo tests for tumor response, survival rates, and disease control over a period of up to 45 months. Researchers will collect tissue samples, monitor side effects, and assess drug levels and immune responses. The study includes regular check-ins to measure how well the cancer responds and to track any adverse events or reactions.

Age: 18Years - 75YearsAll GendersPhase 2
34 locations
P

Actively Recruiting

Researchers are evaluating RC148, both alone and in combination with other therapies, in patients with locally advanced unresectable or metastatic malignant solid tumors. The study includes Phase I, which focuses on assessing safety, tolerability, and determining the maximum tolerated dose and recommended Phase II dose of RC148. Phase II primarily evaluates the effectiveness of RC148 in combination with other treatments, along with safety and pharmacokinetics, while also exploring biomarker correlations with treatment outcomes. Participants receive RC148 as an intravenous infusion either alone or combined with drugs such as docetaxel, RC48, RC88, or bevacizumab. Dosing schedules vary by treatment group, with infusions administered every 2 or 3 weeks depending on the combination. Phase I involves dose escalation with observation for dose-limiting toxicities over 28 days after the first treatment. Phase II includes multiple arms targeting different cancer types with specific combination therapies. Throughout the study, participants undergo regular assessments including monitoring for adverse events, physical exams, laboratory tests, and imaging to measure tumor response using RECIST criteria. Pharmacokinetic and pharmacodynamic evaluations, as well as immunogenicity tests, are conducted. The trial lasts up to 15 months, covering safety and efficacy outcomes. Researchers also collect tumor samples for biomarker analysis and monitor participants for long-term treatment effects and tolerability.

Age: 18Years +All GendersPhase 1Phase 2
31 locations
O

Actively Recruiting

Psoriasis is a chronic, recurring inflammatory disease influenced by genetics and environmental factors, marked by skin lesions that can affect multiple organs. Researchers are evaluating the effectiveness of different treatments chosen by patients in real-world clinical settings, comparing phototherapy, traditional systemic therapies, and biologics among Chinese psoriasis patients. This observational study aims to gather real-world evidence under routine care without intervention. Patients diagnosed with psoriasis by dermatologists choose their preferred treatments, which may include phototherapy, traditional systemic drugs, or biologics. The study does not assign treatments but observes outcomes as patients follow their chosen therapies. Data collection is supported through a phone application called Psoriasis New World, and the study includes multiple centers. Participants will be assessed regularly for treatment effectiveness using measures such as the Psoriasis Area and Severity Index PASI, Physician and Investigator Global Assessments, Body Surface Area affected, and Dermatology Life Quality Index. Adverse events and laboratory tests, including liver function, will be monitored throughout up to 12 months. The primary outcome is the percentage of patients achieving complete skin clearance PASI 100 at 6 months, with additional follow-up evaluations at 12 months.

All AgesAll Genders
29 locations
R

Actively Recruiting

Researchers are evaluating the combination of trastuzumab and bevacizumab as a first-line maintenance treatment for women with epithelial ovarian cancer. This randomized, open-label, multicenter phase IbIII clinical trial is designed to assess safety, tolerability, and effectiveness of this combination compared to bevacizumab alone. Participants have stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer and have completed first-line platinum-based chemotherapy plus bevacizumab without disease progression. The trial has two phases Phase Ib focuses on safety and tolerability of SHR-A1811 trastuzumab combined with bevacizumab as maintenance therapy. Phase III compares efficacy and safety of the combination against bevacizumab alone as maintenance therapy. Participants receive assigned treatments following completion of first-line platinum-based chemotherapy plus bevacizumab. The study uses a randomized, parallel design to allocate participants into two groups. Participants undergo regular assessments including monitoring for dose-limiting toxicity within 21 days and progression-free survival over approximately 3 years with evaluations every 12 weeks initially, then every 24 weeks. Additional measures include adverse events, drug levels, antibody responses, overall survival, response rates, disease control, duration of response, time to progression, tumor marker response, and time to next treatment. Safety and efficacy data are collected throughout treatment and follow-up periods, lasting until study completion in 2030.

Age: 18Years +FEMALEPhase 3
3 locations
R

Actively Recruiting

Researchers are evaluating the efficacy and safety of BR005-036C tablets compared to placebo in adults experiencing acute migraine attacks, including those with or without aura. This phase IIIII, multicenter, randomized, double-blind study aims to better understand how well BR005-036C works to relieve migraine symptoms and how it compares to placebo treatment. Participants are randomly assigned to take one of two doses of BR005-036C oral tablets or a matching placebo tablet. The study assesses the medications effects shortly after dosing, focusing on relief from pain and bothersome symptoms within two hours. The trial includes a treatment period with close monitoring for up to nine days after taking the study drug. During the study, participants will be monitored for migraine pain relief, freedom from symptoms, use of rescue medications, and functional ability after dosing. Researchers will track adverse events and other safety measures throughout the treatment period. The primary outcomes focus on pain freedom and symptom relief two hours after dosing, with additional assessments up to 48 hours. Participants involvement includes medication dosing and follow-up visits to assess their response and safety.

Age: 18Years +All GendersPhase 2Phase 3
83 locations
E

Actively Recruiting

Researchers are evaluating the impact of Guideline-Directed Medical Therapy GDMT on managing uncontrolled asthma in patients who are already using medium- to high-dose inhaled corticosteroids combined with long-acting beta2 agonists ICS-LABA. This prospective, multicenter, cluster-randomized trial in China aims to assess whether GDMT can improve disease management by guiding physicians and specialized nurses in diagnosis and treatment. The study involves approximately 540 participants across 60 hospitals, with sites randomly assigned to either the intervention or control group to compare usual care with GDMT-guided care. Participants in the intervention group receive care from physicians trained in GDMT protocols, supported by specialized nurses who provide patient education and follow-up reminders. The intervention includes routine training, GDMT education, clinical monitoring every 12 weeks, targeted training, and material revision, all implemented at the hospital level. The control group continues with usual clinical care without additional GDMT intervention. The intervention period lasts up to 48 weeks with follow-up visits every 12 weeks. During the study, participants undergo assessments including demographic data collection, asthma exacerbation monitoring, medication use tracking, asthma control tests ACT scores, lung function tests, quality of life questionnaires SGRQ scores, and medical cost evaluations. Researchers will measure changes in physician behavior, patient outcomes, and healthcare resource use. The primary outcomes focus on the proportion of participants with a written diagnosis of severe asthma at 24 and 48 weeks and the annualized asthma exacerbation rate at 48 weeks.

All AgesAll GendersPhase Not Applicable
20 locations
S

Actively Recruiting

Researchers are evaluating whether combining aggressive intravenous hydration with indometacin is more effective at preventing pancreatitis after pancreatic Extracorporeal Shock Wave Lithotripsy ESWL compared to using indometacin alone. This multicenter, randomized, controlled trial focuses on patients with painful chronic pancreatitis who are scheduled for ESWL to treat pancreatic duct stones. The study aims to improve understanding of pancreatitis prevention following ESWL and reduce related complications. Participants will be randomly assigned to one of two groups. One group will receive a rectal administration of 100mg indometacin 30 minutes before ESWL along with aggressive intravenous hydration using lactated Ringers solution, delivered as 20 mLkg within 60 minutes from the start of ESWL followed by 3 mLkg per hour for 8 hours. The other group will receive the same indometacin dose but only restricted hydration measures without aggressive intravenous fluids. Both interventions are carefully monitored during the procedure. During the trial, researchers will measure the incidence of pancreatitis within 24 hours after ESWL as the primary outcome. Additional assessments include severity of pancreatitis, incidence of other post-ESWL complications, fluid overload, transient adverse events within 24 hours, and length of hospitalization over one month. Participants will be evaluated at multiple time points, with careful monitoring of safety and treatment effects throughout the study period, which extends up to December 2027.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
10 locations
E

Actively Recruiting

Researchers are evaluating GI001, an in vivo CD19-targeted CAR-T cell therapy, in adults with relapsed or refractory B-cell Non-Hodgkin Lymphoma B-NHL and B-cell Acute Lymphoblastic Leukemia B-ALL. This open-label, multi-cohort study aims to assess the safety, tolerability, and early effectiveness of GI001. Unlike traditional CAR-T therapies that require lab-based cell manufacturing, GI001 is given directly to patients through intravenous infusion to create CAR-T cells inside the body. The study has two main phases a Dose-Escalation Phase and a Dose-Expansion Phase. The Dose-Escalation Phase tests four increasing dose levels to find the safest and most effective dose, using an accelerated and then standard dose-escalation design. The Dose-Expansion Phase enrolls more participants at the recommended doses to further assess safety, clinical response, and how the therapy behaves in the body. GI001 is given as a single intravenous infusion, with recommended premedication before treatment and no lymphodepleting conditioning. Participants undergo screening and baseline tests before treatment, receive the infusion on Day 0, and are hospitalized for at least 14 days for close monitoring. Safety is watched closely for 28 days after infusion, with follow-up visits up to 24 months and a long-term follow-up period lasting 15 years to monitor survival and any delayed effects. Researchers measure adverse events, vital signs, laboratory values, immune cell levels, and clinical response throughout the study.

Age: 18Years - 75YearsAll GendersEarly Phase 1
1 location
P

Actively Recruiting

Researchers are evaluating XNW28012 in adults with advanced solid tumors who have not responded to or cannot tolerate standard anti-tumor treatments. This phase 1, first-in-human study is open-label and multicenter, aiming to assess the safety, tolerability, pharmacokinetics, and early signs of anti-tumor activity of XNW28012. The study includes two parts dose escalation and dose expansion, focusing on multiple solid tumor types such as ovarian, cervical, pancreatic, and colorectal cancers. Participants will receive XNW28012 intravenously every three weeks at increasing doses determined by a Bayesian Optimal Interval method, starting from 0.6 mgkg up to 7.5 mgkg during the dose escalation phase. Treatment continues until intolerable side effects, disease progression without benefit, or withdrawal of consent. The first treatment cycle is carefully monitored for dose-limiting toxicities to guide safe dosing. The subsequent dose expansion part involves treating patients at the recommended dose identified from the escalation phase. Throughout the study, participants will undergo regular safety assessments, including monitoring treatment-related adverse events, organ function tests, and tumor response evaluations. Imaging and clinical evaluations for tumor progression will occur at scheduled intervals up to one year. Researchers will also measure drug levels, immune response to the drug, and tumor control outcomes. Participants are followed closely to evaluate treatment effects, side effects, and overall health status during and after therapy.

Age: 18Years +All GendersPhase 1Phase 2
24 locations